Response to: 'Comment on: standardisation of myositis-specific antibodies: where are we today?' by Infantino <i>et al</i>.

Rönnelid, Johan; Espinosa-Ortega, Fabricio; Lundberg, Ingrid E

Response to: 'Comment on: standardisation of myositis-specific antibodies: where are we today?' by Infantino et al.

Rönnelid, Johan; Espinosa-Ortega, Fabricio; Lundberg, Ingrid E.

Affiliation

Rönnelid J; Department Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Espinosa-Ortega F; Medicine, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lundberg IE; Medicine, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden ingrid.lundberg@ki.se.

Ann Rheum Dis ; 80(7): e116, 2021 07.

Article in En | MEDLINE | ID: mdl-31615753

Subject(s)

Myositis; Polymyositis; Antibodies; Humans

Key words

autoantibodies; dermatomyositis; polymyositis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymyositis / Myositis Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2021 Document type: Article Affiliation country: Sweden Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google